Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer

Hinchcliff, EM; Knisely, A; Adjei, N; Fellman, B; Yuan, Y; Patel, A; Xu, C; Westin, SN; Sood, AK; Soliman, PT; Shafer, A; Fleming, ND; Gershenson, DM; Vikram, R; Bathala, T; Vining, D; Ganeshan, DM; Lu, KH; Sun, CC; Meyer, LA; Jazaeri, AA

Jazaeri, AA (通讯作者)，Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol & Reprod Med, 1155 Pressler St,Unit 1362, Houston, TX 77030 USA.

CANCER, 2023; ():

Abstract

BackgroundSingle-agent immune checkpoint inhibitors (ICIs) have demonstrated limited responses in recurrent ovarian cancer; however, 30%-40% of patien......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索